Literature DB >> 11422053

Paraneoplastic pemphigus: an association with fludarabine?

C Gooptu1, T J Littlewood, P Frith, C C Lyon, A J Carmichael, S Oliwiecki, A MacWhannell, M Amagai, T Hashimoto, D Dean, J Allen, F Wojnarowska.   

Abstract

Paraneoplastic pemphigus is a relatively recently described immunobullous disease with characteristic features. We report three cases of paraneoplastic pemphigus in adult men with chronic lymphocytic leukaemia arising within a week of completion of treatment with fludarabine. In all cases, withdrawal of fludarabine and treatment of the blistering was associated with marked cutaneous improvement. Fludarabine, a synthetic nucleoside analogue, which has only been available in Britain since 1994, is known to be associated with autoimmune phenomena and may have been involved in the development of paraneoplastic pemphigus in these cases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11422053     DOI: 10.1046/j.1365-2133.2001.04244.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

1.  Paraneoplastic pemphigus associated with fludarabine use.

Authors:  Ozcan Yildiz; Mustafa Ozguroglu; M Teoman Yanmaz; Hande Turna; Sabiha Gokcen Kursunoglu; Meltem Antonov; Server Serdaroglu; Cuyan Demirkesen; Evin Buyukunal
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

Review 2.  The etiology of paraneoplastic autoimmunity.

Authors:  Emanual Maverakis; Heidi Goodarzi; Lisa N Wehrli; Yoko Ono; Miki Shirakawa Garcia
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

Review 3.  Chronic lymphocytic leukemia and autoimmunity: a systematic review.

Authors:  Kate Hodgson; Gerardo Ferrer; Emili Montserrat; Carol Moreno
Journal:  Haematologica       Date:  2011-01-17       Impact factor: 9.941

4.  Evaluation of cutaneous side-effects associated with chemotherapeutic use in oncological patients.

Authors:  Zeynep Utlu; Handan Bilen
Journal:  Postepy Dermatol Alergol       Date:  2021-10-22       Impact factor: 1.837

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.